Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


What Would It Take To Attract Global Pharmas To Korea?

Executive Summary

What do successful biopharma countries have in common? At a recent biopharma industry seminar in Incheon, South Korea, delegates stressed the importance of creating strong bioclusters if the country is to transform itself into a biopharma-focused nation.

You may also be interested in...

Samsung BioLogics Eyes Global Leadership Via Korean IPO

In its ongoing efforts to become the world's top biopharmaceutical manufacturing company, Samsung BioLogics has decided to launch an initial public offering in the benchmark Korean stock market this year amid weak biotech sentiment in the US. Proceeds from the IPO, poised to be one of the biggest domestic IPOs, will be used for further expansion of its manufacturing facilities.

Bukwang Speeds Lead Asset As It Eyes Danish Operation's Listing

Helped by a hefty financing earlier this year, Bukwang subsidiary Contera Pharma is poised to speed ongoing multinational Phase II trials with its lead asset for Parkinson’s-associated dyskinesia by hiring CNS experts as new top executives, as the Korean firm looks to take it public in ground-breaking move.

GemVax Aims For Alzheimer’s 'Game Changer' As Phase III Approaches

After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts